Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents

Current Opinion in Rheumatology

Volumn 26, Issue 4, 2014, Pages 395-403

  Juan, Joshua ^a   Feld, Jordan J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

anti TNF therapy; antiviral therapy; hepatitis B reactivation; hepatitis C; prophylaxis; rituximab

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; MERCAPTOPURINE; METHOTREXATE; OFATUMUMAB; PREDNISONE; RITUXIMAB; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84901832719     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000067     Document Type: Review

References (63)

1. Chisari FV, Ferrari C. Viral hepatitis. Viral pathogenesis. Philadelphia: Lippincott-Raven; 1997.
2. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3:41-46.
3. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010; 58:258-266.
4. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34 (4 Pt 1):617-624. (Pubitemid 32927983)
5. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43 (2 Suppl 1): S173-S181.
6. Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26:116-129. (Pubitemid 43668254)
7. European Asscociation For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
8. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011; 55:183-191.
9. Chen MT, Billaud JN, Guidotti LG, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101:14913-14918. (Pubitemid 39410774)
10. Liaw YF, Chu CM, Huang MJ, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastro-enterology 1983; 84:216-219. (Pubitemid 13224257)
11. Manno M, Camma C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127:756-763. (Pubitemid 39208409)
12. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758. (Pubitemid 38736340)
13. Castells L, Vargas V, Rodriguez F, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8:892-900. (Pubitemid 35154018)
14. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447-449. (Pubitemid 12139868)
15. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005; 41: 1277-1282. (Pubitemid 41532669)
16. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49 (5 Suppl): S156-S165.
17. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastro-enterology 1991; 100:182-188.
18. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43:209-220.
19. Suzuki H, Sata M, Sasaki M, et al. Mutations of glucocorticoid responsive element of HBV DNA. Kurume Med J 1998; 45:171-174.
20. Cheng AL, Hsiung CA, Chen PJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37:1320-1328. (Pubitemid 36667311)
21. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136:1182-1197.
22. Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007; 19:619-625. (Pubitemid 47530884)
23. Moses SE, Lim ZY, Sudhanva M, et al. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006; 78:1560-1563. (Pubitemid 44672497)
24. Park JW, Park KW, Cho SH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastro-enterol 2005; 100:2194-2200.
25. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36. (Pubitemid 26054933)
26. Ganem D, Prince AM. Hepatitis, B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129. (Pubitemid 38298992)
27. Hohler T, et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111:579-582. (Pubitemid 28160904)
28. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90:359-371
29. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29:1021-1029.
30. Yazdany J, Calabrese L. Preventing hepatitis B reactivation in immunosup-pressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken) 2010; 62:585-589.
31. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011; 31 (Suppl 1):104-110.
32. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605-611.
33. Papamichalis P, Alexiou A, Boublou M, et al. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt preemptive therapy? Clin Res Hepatol Gastroenterol 2012; 36:84-93.
34. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89:255-262.
35. Yeo W, Zee B, Chan PK, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90:1306-1311. (Pubitemid 38586252)
36. McGuinness PH, Bishop GH, Painter DM, et al. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996; 23:676-687. (Pubitemid 26111977)
37. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gas-troenterology 2003; 125:1742-1749. (Pubitemid 37500439)
38. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lympho-ma: a randomized trial. Hepatology 2008; 47:844-853. (Pubitemid 351449676)
39. Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol 2012; 5:359-370.
40. Lok AS, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines. Hepatology 2009; 50:1-36.
41. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
42. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57 (Rr-8):1-20.
43. Singh JA, Furst DE, Bharat A, et al. update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheu-matic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625-639.
44. Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30:3167-3173.
45. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15 (Suppl):E3-E6.
46. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26:401-412.
47. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1):S35-S46. (Pubitemid 35253462)
48. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52:889-900.
49. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13:219-226. (Pubitemid 46351647)
50. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22:120-141.
51. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012; 55 (Suppl 1):S33-S42.
52. Rockstroh JK. Management of hepatitis C/HIV coinfection. Curr Opin Infect Dis 2006; 19:8-13. (Pubitemid 43032433)
53. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33 (Suppl 1):56-62.
54. Kahraman A, Witzke O, Scherag A, et al. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol 2011; 75:16-25.
55. Chan AJ, Lake JR. Immunosuppression in HCV-positive liver-transplant recipients. Curr Opin Organ Transplant 2012; 17:648-654.
56. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
57. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014; 89:95-106.
58. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10:369-375. (Pubitemid 26364819)
59. Castera L, Forns X, Alberti A. Noninvasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
60. Sansonno D, Carbone A, De Re V, et al. Hepatitis C virus infection, cryoglo-bulinaemia, and beyond. Rheumatology (Oxford) 2007; 46:572-578. (Pubitemid 46523298)
61. Saadoun D, Delluc A, Piette JC, et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008; 20:23-28. (Pubitemid 351339428)
62. Dore MP, Fattovich G, Sepulveda AR, et al. Cryoglobulinemia related to hepatitis C virus infection. Dig Dis Sci 2007; 52:897-907. (Pubitemid 46481268)
63. Cacoub P, Terrier B, Saadoun D. Hepatitis, C virus-induced vasculitis: therapeutic options. Ann Rheum Dis 2014; 73:24-30.